Altimmune, Inc. (ALT)
1.58
-0.06
(-3.95%)
USD |
NASDAQ |
Nov 16, 13:56
Altimmune Shareholders Equity (Quarterly) : 443.57M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 443.57M |
| June 30, 2026 | 474.21M |
| March 31, 2026 | 283.99M |
| December 31, 2025 | 224.89M |
| September 30, 2025 | 185.60M |
| June 30, 2025 | 161.37M |
| March 31, 2025 | 142.16M |
| December 31, 2024 | 123.51M |
| September 30, 2024 | 133.38M |
| June 30, 2024 | 152.53M |
| March 31, 2024 | 172.94M |
| December 31, 2023 | 194.10M |
| September 30, 2023 | 150.40M |
| June 30, 2023 | 167.71M |
| March 31, 2023 | 167.73M |
| December 31, 2022 | 185.29M |
| September 30, 2022 | 205.03M |
| June 30, 2022 | 194.54M |
| March 31, 2022 | 184.87M |
| December 31, 2021 | 199.13M |
| September 30, 2021 | 209.26M |
| June 30, 2021 | 241.28M |
| March 31, 2021 | 246.44M |
| December 31, 2020 | 225.88M |
| September 30, 2020 | 199.71M |
| Date | Value |
|---|---|
| June 30, 2020 | 79.52M |
| March 31, 2020 | 41.90M |
| December 31, 2019 | 45.52M |
| September 30, 2019 | 49.38M |
| June 30, 2019 | 56.22M |
| March 31, 2019 | 59.32M |
| December 31, 2018 | 48.31M |
| September 30, 2018 | 39.68M |
| June 30, 2018 | 36.32M |
| March 31, 2018 | 46.49M |
| December 31, 2017 | 48.68M |
| September 30, 2017 | 57.07M |
| June 30, 2017 | 75.98M |
| March 31, 2017 | 18.05M |
| December 31, 2016 | 32.21M |
| September 30, 2016 | 136.38M |
| June 30, 2016 | 24.25M |
| March 31, 2016 | 15.63M |
| December 31, 2015 | 16.65M |
| September 30, 2015 | 17.67M |
| June 30, 2015 | 18.34M |
| March 31, 2015 | 20.02M |
| December 31, 2014 | 18.27M |
| September 30, 2014 | 18.11M |
| June 30, 2014 | 10.86M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Imunon, Inc. | 2.622M |
| Taysha Gene Therapies, Inc. | 356.97M |
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 495.65M |
| Total Liabilities (Quarterly) | 52.08M |
| Debt to Equity Ratio | 0.0816 |
| Current Ratio | 23.91 |
| Net Debt Paydown Yield | -0.73% |